Biovac to start local production of Sanofi and Pfizer vaccines

Organisation: Position: Deadline Date: Location:

The Biovac Institute , a SA public-private partnership, will start local production of Sanofi’s Hexavalent vaccine in 2020 and Pfizer’s anti-pneumonia Prevnar 13 vaccine in 2021, boosting the supply of life-saving drugs in its main market, says its CEO. Business Day reports that local output of the two vaccines is a step-change for Biovac, a public-private partnership 47.5%-owned by the South African government, with long-term ambitions of expanding sales into the continent.

The new production lines follow years of technology transfers and skills upgrades with partners Sanofi and Pfizer in Africa’s largest pharmaceutical market. The companies were tight-lipped about commercial details of the partnership.

“We start production of Hexavalent in Q3 2020,” Biovac CEO Morena Makhoana is quoted in the report as saying.

The plant, modernised at a cost of about R1bn, will produce 4m doses of Hexavalent vaccine a year and has the capacity to ramp up significantly as the company explores new markets in Namibia, Mozambique and Angola, he said.

The report says the South African government buys about 95% of the total 25m doses of vaccine supplied annually by Biovac, covering diseases such as tuberculosis, cervical cancer and influenza.

Biovac’s dose of Hexavalent, a six-in-one vaccine for several diseases including diphtheria, tetanus and polio, is the only one in the world that is fully liquid, Makhoana said. It does not have to be mixed before injecting, which makes it easier to administer in remote and resource-poor clinics across Africa, he added. “On this particular six-in-one vaccine, we are the only tech transfer partner with Sanofi in the world, so we are very proud,” Makhoana said.

Sanofi said it will continue to invest in South Africa’s vaccine programme as it looks to bolster its position. “South Africa, and Africa for that matter, is an emerging market and showing strong growth year on year and hence will remain a priority for Sanofi,” Merilynn Matthew, who heads Sanofi’s SA vaccines unit, said.

About one-in-five African children do not get immunised, with measles alone accounting for 61,000 preventable deaths a year on the continent, according to the World Health Organisation.

The report says Biovac, the rest of which is owned by a consortium led by local investment holding firm Immunotek, has also made progress preparing Pfizer’s pneumonia vaccine for infants, Prevnar 13. It expects full output of 3m doses to start in the first half of 2021.

Under a five-year agreement signed with Pfizer in 2015, Biovac only packaged labelled syringes but is now acquiring the formulation and filling processes ahead of the new product line launch.

“Security of supply is one big issue, and the second is the economic benefits local production brings, while making sure that prices are equally benchmarked and South Africa pays a fair price in line with other middle-income countries such as Brazil or Turkey,” Makhoana said.

At the partnership launch four years ago, a cabinet minister said the pneumonia vaccine alone used up 40% of South Africa’s total budget for vaccines, with the government then paying about R185 per single dose of imported Prevenar 13. Each infant will eventually need three doses. Pfizer did not provide the current cost of the vaccine.

“The technology transfer process has enabled significant knowledge transfer, job creation and direct investment,” said Rhulani Nhlaniki, Pfizer’s country manager.

Business Day report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.